245 filings
Page 2 of 13
8-K
law 6o6fybdgo6f
2 Mar 23
DBV Technologies Reports Full Year 2022 Financial Results and Business Update
6:29pm
8-K
kslaobx98g
23 Dec 22
DBV Technologies Announces FDA Has Lifted Partial Clinical Hold on VITESSE Phase 3 Pivotal Trial
9:59am
8-K
33e29
3 Nov 22
DBV Technologies Reports Third Quarter Financial Results and Business Update
5:18pm
8-K
ewb0ds
4 Oct 22
DBV Technologies Announces Appointment of New Chair of its Audit Committee and Appointment of Daniele Guyot-Caparros to Board of Directors
7:32am
8-K
opkqama
21 Sep 22
DBV Technologies Provides Clinical Update on VITESSE Phase 3 Trial
7:49pm
8-K
4eco13fesv5fawsp5r
7 Sep 22
DBV expects to screen the first patient in Q4 2022 and anticipates topline results for the VITESSE study to read out in Q1 2025
7:09pm
8-K
g19m1vgtoxy2nqgpzx22
1 Aug 22
DBV Technologies Reports Second Quarter 2022 Financial Results
4:45pm
8-K
kfzer89vay8r
13 Jun 22
DBV Technologies Announces Private Placement Financing of $194 Million
4:34pm
8-K
ooeneb5uu 990gjf0
7 Jun 22
DBV Technologies Announces Positive Topline Results from Phase 3 EPITOPE Trial of Viaskin Peanut in Peanut-Allergic Toddlers
5:30pm
8-K
2a1 wa6wotzchne
16 May 22
Submission of Matters to a Vote of Security Holders
4:33pm
8-K
ofkd bm3u0f4dsqdi
2 May 22
Other Events
4:58pm
8-K
custb1
2 May 22
DBV Technologies Reports Recent Business Developments and First Quarter 2022 Financial Results
4:14pm
8-K
sbcc90hqfrip4
9 Mar 22
DBV Technologies Announces Filing of 2021 Annual Report on Form 10-K and 2021 Universal Registration Document
4:50pm
8-K
vdncat munx2
3 Mar 22
DBV Technologies Reports Full Year 2021 Financial Results and Recent Business Updates
4:29pm
8-K
xc3 rcuj9s3k
20 Dec 21
DBV Technologies Provides Update on Investigational Viaskin™ Peanut
4:24pm
8-K
ey5oihpxjhbk3f
26 Oct 21
DBV Technologies Reports Third Quarter 2021 Financial
4:22pm
8-K
g7e9ouyw 0c
2 Aug 21
DBV Technologies Reports Second Quarter 2021 Financial Results and Recent Business Developments
4:32pm
8-K
c1csvxrkq yxfpcch9
24 May 21
Amendments to Articles of Incorporation or Bylaws
4:35pm
8-K
65ui53b otu0njzmwf
3 May 21
Results of Operations and Financial Condition
4:12pm
8-K/A
37u20f
30 Apr 21
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:32pm